| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $931K | +107.0% | +5.9% |
| SG&A Expense | $2.2M | +73.4% | +40.7% |
| Operating Income | -$3.1M | -82.2% | -28.2% |
| Net Income | -$3.1M | -35.0% | -24.5% |
| EPS (Basic) | -$1.96 | +36.8% | -415.8% |
| EPS (Diluted) | -$1.96 | +36.8% | -415.8% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $11.4M | +477.8% | +262.7% |
| Current Assets | $12.7M | +493.8% | +208.9% |
| Total Assets | $12.7M | +493.8% | +144.1% |
| Total Liabilities | $2.9M | -32.7% | +35.2% |
| Stockholders' Equity | $9.8M | +562.1% | +219.5% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$6.4M | — | — |
| Financing Cash Flow | $16.9M | — | — |